In March 2024, the leaders of the High-Tech Products I&E Department of Jilin Provincial Department of Commerce visit Qijijan Bio-Pharmaceutical for investigation.

1.  2024.5.7- 2024.5.9, CPHI North America to be held in Philadelphia USA, Address: Pennsylvania Covention Center Philadelphia,  Booth number: 1602   2.  2024.6.4-2024.6.6 FCE Pharma to be held in Sao Paulo Brazil, Address: Sao Paulo Expo, Booth number: CH76

API (Butylphthalein) R&D Site, Production Site Verification and GMP Compliance Inspection of Jilin Qijian Bio-Pharmaceutical Co.,Ltd successfully passed.

CPHI Worldwide will be held in Barcelona, Spain on October 24-26, 2023.Jilin Qijian Bio-Pharmaceutical Co.,Ltd will attend the exhibition, Booth No: 80Q19, welcome to visit us.

In early 2022, Jilin Provincial Food and Drug Administration announced our "Drug export license for anabolic agents and peptide hormones" on website, it means that Qijian has become an approved enterprise for export human growth hormone (HGH) API in Jilin Province. Moreover in April 2021 Qijian obtained the "Drug Production License" for product HGH which updated and issued by CFDA, and the quality of HGH products meet the US FDA and EU GMP standards. In the new year, we will continue to improve our management level and provide customers with better products. 注： 出口准许证获批公示连接地址 吉林省药品监督管理局核（换）发《药品生产许可证》公告（2022年第1期）公示连接地址 药品生产许可查询地址